KNTE
RhumbLine Advisers’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-2,933
| Closed | -$7.8K | – | 4411 |
|
|
2024
Q1 | $7.8K | Hold |
2,933
| – | – | ﹤0.01% | 3914 |
|
|
2023
Q4 | $6.95K | Hold |
2,933
| – | – | ﹤0.01% | 3927 |
|
|
2023
Q3 | $4.11K | Sell |
2,933
-1,667
| -36% | -$2.33K | ﹤0.01% | 4016 |
|
|
2023
Q2 | $13.9K | Sell |
4,600
-47,773
| -91% | -$145K | ﹤0.01% | 3868 |
|
|
2023
Q1 | $327K | Buy |
52,373
+6,328
| +14% | +$39.5K | ﹤0.01% | 2585 |
|
|
2022
Q4 | $281K | Buy |
46,045
+272
| +0.6% | +$1.66K | ﹤0.01% | 2699 |
|
|
2022
Q3 | $547K | Buy |
45,773
+2,816
| +7% | +$33.7K | ﹤0.01% | 2458 |
|
|
2022
Q2 | $542K | Buy |
42,957
+10,878
| +34% | +$137K | ﹤0.01% | 2465 |
|
|
2022
Q1 | $361K | Buy |
32,079
+1,809
| +6% | +$20.4K | ﹤0.01% | 2573 |
|
|
2021
Q4 | $536K | Buy |
30,270
+298
| +1% | +$5.28K | ﹤0.01% | 2481 |
|
|
2021
Q3 | $690K | Buy |
29,972
+14,517
| +94% | +$334K | ﹤0.01% | 2403 |
|
|
2021
Q2 | $360K | Buy |
15,455
+3,758
| +32% | +$87.5K | ﹤0.01% | 2717 |
|
|
2021
Q1 | $364K | Buy |
+11,697
| New | +$364K | ﹤0.01% | 2631 |
|